Impact of risk score calculations in choosing front‐line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase

B Hu, BN Savani - European journal of haematology, 2014 - Wiley Online Library
The approval of multiple tyrosine kinase inhibitors targeting BCR‐ABL has broadened the
number of available therapeutic options for chronic myeloid leukemia in the chronic phase …
被引用次数：28 相关文章

Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

B Hu, BN Savani - European Journal of Haematology, 2014 - search.ebscohost.com
The approval of multiple tyrosine kinase inhibitors targeting BCR-ABL has broadened the
number of available therapeutic options for chronic myeloid leukemia in the chronic phase …

Impact of risk score calculations in choosing front‐line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase

B Hu, BN Savani - European Journal of Haematology, 2014 - infona.pl
The approval of multiple tyrosine kinase inhibitors targeting BCR‐ABL has broadened the
number of available therapeutic options for chronic myeloid leukemia in the chronic phase …

Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

B Hu, BN Savani - European Journal of Haematology, 2014 - europepmc.org
The approval of multiple tyrosine kinase inhibitors targeting BCR-ABL has broadened the
number of available therapeutic options for chronic myeloid leukemia in the chronic phase …

Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase

B Hu, BN Savani - European journal of haematology, 2014 - pubmed.ncbi.nlm.nih.gov
The approval of multiple tyrosine kinase inhibitors targeting BCR-ABL has broadened the
number of available therapeutic options for chronic myeloid leukemia in the chronic phase …

Impact of risk score calculations in choosing front‐line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase

B Hu, BN Savani - European Journal of Haematology, 2014 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The approval of multiple tyrosine kinase
inhibitors targeting< jats: styled-content style=" fixed-case"> BCR</jats: styled-content>‐< …